about
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular CarcinomaGuadecitabine Extension StudyStudy Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast CancerTabelecleucel in Combination With Pembrolizumab in Subjects With EBV+ Nasopharyngeal Carcinoma (ATA129-NPC-202)A Study of SC-011 Alone and in Combination With ABBV-181 in Subjects With Relapsed or Refractory Small Cell Lung CancerLong-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)PaRTNer: Patient Reported Outcomes and Financial Toxicity in Head and Neck Cancer A Pilot, Survey Based StudyPembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)Eltrombopag for the Prevention of Chemotherapy Induced ThrombocytopeniaTrial Comparing PLA to HIGRT Therapy (PROVE-HCC)Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced MalignanciesA Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical ResectionA Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)An Investigational Immuno-therapy Study of Nivolumab or Placebo in Patients With Resected Esophageal or Gastroesophageal Junction Cancer
P6153
Q61862160-13B00509-99A8-4F99-B7CC-B12B24F86E40Q61907444-9DD40CC7-A88A-4101-AE08-4367D98D3938Q61932852-44082181-5AD4-4CAF-8315-2FB0990418FCQ62031467-0742C8BD-C7F1-4E76-86AF-E9190A4A54C1Q62063047-99C28617-9BCA-415A-AEB7-35CD13130EACQ62809147-C433D6A4-4353-47EF-86D8-77CEC8D49483Q62822975-A3D36405-7050-4E5C-A9D2-4FD7D16A452AQ63229610-E5EF526D-16FA-4A17-A861-33E2F0827809Q63320474-1F53FBC5-AB08-4946-83F7-F3CD212B40B7Q63405363-112E3106-3CC4-4FD1-8366-E9DBF1780AB4Q63535194-89969BC6-1397-4EAD-9F97-9A970988384FQ63571371-904478AF-C3FF-4302-ABBD-D6FF086566CEQ63573156-20E7DE6B-0666-4ED1-A6B0-33748E9C182EQ64151359-FB896849-99F5-46D2-AC5C-0BF8B70434EA
P6153
description
cancer treatment center
@en
name
Duke Cancer Center
@en
type
label
Duke Cancer Center
@en
altLabel
Duke Cancer
@en
Duke University Cancer Center
@en
prefLabel
Duke Cancer Center
@en